158 related articles for article (PubMed ID: 32111493)
1. Synergistic Apoptotic Effects of Bortezomib and Methylstat on Multiple Myeloma Cells.
Kacı FN; Kiraz Y; Çekdemir D; Baran Y
Arch Med Res; 2020 Apr; 51(3):187-193. PubMed ID: 32111493
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Potentials of Inhibition of Jumonji C Domain-containing Demethylases in Acute Myeloid Leukemia.
Koca D; Hastar N; Engür S; Kiraz Y; Ulu GT; Çekdemir D; Baran Y
Turk J Haematol; 2020 Feb; 37(1):5-12. PubMed ID: 31833715
[TBL] [Abstract][Full Text] [Related]
3. [Study of the effects
Tian Y; Li LH; Yang GZ; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):976-981. PubMed ID: 27995884
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3.
Lin L; Chen D; Xiang ZF; Pei RZ; Zhang PS; Liu XH; Du XH; Lu Y
Cancer Biomark; 2017 Aug; 20(2):217-224. PubMed ID: 28869453
[TBL] [Abstract][Full Text] [Related]
5. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Ma Y; Liu W; Zhang L; Jia G
Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27.
Li J; Zhang X; Shen J; Guo J; Wang X; Liu J
Mol Med Rep; 2019 Sep; 20(3):2410-2418. PubMed ID: 31322176
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
9. Decitabine enhances bortezomib treatment in RPMI 8226 multiple myeloma cells.
Cao Y; Qiu GQ; Wu HQ; Wang ZL; Lin Y; Wu W; Xie XB; Gu WY
Mol Med Rep; 2016 Oct; 14(4):3469-75. PubMed ID: 27571872
[TBL] [Abstract][Full Text] [Related]
10. Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines.
Barbosa RSS; Dantonio PM; Guimarães T; de Oliveira MB; Fook Alves VL; Sandes AF; Fernando RC; Colleoni GWB
Biochem Biophys Res Commun; 2019 Nov; 519(3):597-604. PubMed ID: 31540690
[TBL] [Abstract][Full Text] [Related]
11. New indication for therapeutic potential of an old well-known drug (propranolol) for multiple myeloma.
Kozanoglu I; Yandim MK; Cincin ZB; Ozdogu H; Cakmakoglu B; Baran Y
J Cancer Res Clin Oncol; 2013 Feb; 139(2):327-35. PubMed ID: 23080133
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis induction preceded by mitochondrial depolarization in multiple myeloma cell line U266 by 2-aminophenoxazine-3-one.
Shirato K; Imaizumi K; Miyazawa K; Takasaki A; Mizuguchi J; Che XF; Akiyama S; Tomoda A
Biol Pharm Bull; 2008 Jan; 31(1):62-7. PubMed ID: 18175943
[TBL] [Abstract][Full Text] [Related]
13. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.
Chen G; Xu Z; Chang G; Hou J; Hu L; Zhang Y; Yu D; Li B; Chang S; Xie Y; Zhang Y; Wei R; Wu H; Xiao W; Sun X; Tao Y; Gao L; Dai B; Shi J; Zhu W
Oncol Rep; 2017 Jul; 38(1):488-496. PubMed ID: 28560392
[TBL] [Abstract][Full Text] [Related]
14. ANXA7 promotes the cell cycle, proliferation and cell adhesion-mediated drug resistance of multiple myeloma cells by up-regulating CDC5L.
Liu H; Guo D; Sha Y; Zhang C; Jiang Y; Hong L; Zhang J; Jiang Y; Lu L; Huang H
Aging (Albany NY); 2020 Jun; 12(11):11100-11115. PubMed ID: 32526706
[TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
Jia C; Kong D; Guo Y; Li L; Quan L
Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
17. BAY-11-7082 induces apoptosis of multiple myeloma U266 cells through inhibiting NF-κB pathway.
Wang Y; Zhang XL; Sun CM
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2564-2571. PubMed ID: 29771406
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic effects of non-edible parts of Punica granatum on human multiple myeloma cells.
Kiraz Y; Neergheen-Bhujun VS; Rummun N; Baran Y
Tumour Biol; 2016 Feb; 37(2):1803-15. PubMed ID: 26318303
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib.
Engür S; Dikmen M
Acta Clin Belg; 2017 Dec; 72(6):391-398. PubMed ID: 28327055
[TBL] [Abstract][Full Text] [Related]
20. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
Zhang L; Ma YP; Jia G
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):926-31. PubMed ID: 23363750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
